CRYOPORT, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CRYOPORT, INC. (CYRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.88 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CRYOPORT, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.71, a 57.75% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $15.88.
- CRYOPORT, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-06-30 was $0.27, a 47.06% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2012-06-30 was $0.51.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|---|
| 2026-06-30 | $8.88 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | $6.87 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.81 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $6.71 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $13.94 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $14.26 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $15.88 10-Q · filed 2024-05-08 | |||
| 2023-09-30 | $21.03 10-Q · filed 2023-11-09 | |||
| 2015-05-31 | $7.80 10-Q · filed 2015-08-06 | |||
| 2013-12-31 | $0.27 10-Q · filed 2014-02-13 | |||
| 2013-09-30 | $0.27 10-Q · filed 2013-11-18 | |||
| 2013-06-30 | $0.27 10-Q · filed 2013-08-14 | |||
| 2012-12-31 | $0.28 10-Q · filed 2013-02-14 | |||
| 2012-09-30 | $0.42 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $0.51 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |